Core Viewpoint - First Watch Restaurant Group, Inc. announces the retirement of Chief Financial Officer Mel Hope, who will assist in the transition to his successor, ensuring continuity in financial leadership [1][2][3] Company Leadership Transition - Mel Hope has been with First Watch since 2018 and has played a crucial role in guiding the company through its IPO and various growth phases [2] - The company is actively seeking both internal and external candidates for the CFO position, with Hope expected to remain until a successor is appointed [1][2] Company Overview - First Watch is recognized as a leading Daytime Dining concept, specializing in made-to-order breakfast, brunch, and lunch using fresh ingredients [3] - The company operates over 630 restaurants across 32 states and has received multiple awards, including 1 Best Breakfast by Newsweek's Readers' Choice Awards 2025 [3] - First Watch has a commitment to community impact, having raised approximately $2.0 million through donations linked to children's meals served [3]

Q4 revenue increased 30% year-over-year to a record $192 million, driven by robust marketplace growth.Q4 marketplace revenue growth accelerated to 33% year-over-year, driven by strong enterprise growth and expanded networks of buyers and suppliers.Q4 gross profit increased 27% year-over-year to a record $75.2 million, driven by strong marketplace growth and marketplace gross margin expansion.Q4 Adjusted EBITDA improved $7.3 million year-over-year to Adjusted EBITDA of $8.4 million, driven by expanding marke ...

Sanjeev Singh Sahni to Succeed Randy Altschuler as CEO; Altschuler to Become Executive Chair NORTH BETHESDA, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, announced that effective July 1, 2026, Co-founder and Chief Executive Officer, Randy Altschuler, will transition to become the Executive Chair of the Board. Sanjeev Singh Sahni, Xometry’s current President, will succeed Altschuler as Chief Exec ...

Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025; projected re ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Appl ...

― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 20 ...

“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multiple Omicron-virus variants in a modern, COVID-endemic, seropositive population, adding to prior work ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Appl ...

MONTVALE, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference. About Balchem Corporation Balchem Corporati ...

50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a pilot clinical trial led by Memorial ...